Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib Combined With Imatinib in Moderate-to-Severe Palmoplantar Pustulosis
NCT07530367Phase 3Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tofacitinib oral solution, imatinib in palmoplantar pustulosis (PPP), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
tofacitinib oral solutionimatinib
03
Conditions
palmoplantar pustulosis (PPP)
Beyond the preview
Go deeper on NCT07530367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07530367.